Caricamento...
YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models
BACKGROUND AND PURPOSE: Targeted chemotherapy using small-molecule inhibitors of angiogenesis and proliferation is a promising strategy for cancer therapy. EXPERIMENTAL APPROACH: YL529 was developed via computer-aided drug design, de novo synthesis and high-throughput screening. The biochemical, pha...
Salvato in:
| Autori principali: | , , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Blackwell Publishing Ltd
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3753834/ https://ncbi.nlm.nih.gov/pubmed/23594209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.12216 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|